MedTrace Logo

A Study to Evaluate the Real-world Experience and Satisfaction Associated With Ofatumumab

NCT07504783 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 261

Last updated 2026-04-27

No results posted yet for this study

Summary

The aim of this study is to assess physician and patient satisfaction with ofatumumab using data collected from physicians and their multiple sclerosis (MS) patients in real-world clinical practice across the United Kingdom (UK), France, Germany, Italy, Spain, China, Japan, and Brazil.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-22
Primary Completion
2026-04-30
Completion
2026-04-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07504783 on ClinicalTrials.gov